Document is current
Any future updates will be listed below
-
Authors
Dellamonica, David
Ruau, David
Griffiths, Ben
Rossi, Greg
Li, Bob T.
Razavi, Pedram
Di Maio, Thomas
Gonzalez, Tristan
Remorino, Amanda
Reis-Filho, Jorge S.
Menu, Philippe
Gutjahr, Thorsten
Moucquot, Adrien
Diethe, Tom
Naqvi, Hassan
Muken, Ross
Azcue, Pablo
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 23 May 2025
Accepted: 2 October 2025
First Online: 7 November 2025
Competing interests
: D.D., G.R., B.T.L., T.D.M., Tr.G., A.R., J.S.R.-F., Th.G., H.N., and P.A. report employment by and stock ownership/shareholder for AstraZeneca. D.R. is an employee of NVIDIA, a Member of the STFC Innovation & Business Board, and a Member of the Scientific Advisory Board of the Zimin Institute for AI Solutions in Healthcare; D.R. is a minority shareholder of AstraZeneca and NVIDIA. A.M. reports employment by and stock ownership for AstraZeneca and stock ownership for NVIDIA. T.D. reports employment by AstraZeneca. B.G. reports employment by NVIDIA. P.R. has served as a consultant and/or advisory board member, or received Honoraria from Novartis, AstraZeneca, Pfizer, Lilly/Loxo, Prelude Therapeutics, Epic Sciences, Daiichi-Sankyo, Foundation Medicine, Inivata, Natera, Tempus, SAGA Diagnostics, Guardant, and Myriad; P.R. has received institutional grant/funding support from Grail, Novartis, AstraZeneca, EpicSciences, Invitae/ArcherDx, Biothernostics, Tempus, Neogenomics, Biovica, Guardant, Personalis, and Myriad. P.M. and R.M. report employment by SOPHiA GENETICS.
